A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Stopped early · Phase 1
Conditions studied: Isocitrate Dehydrogenase Gene Mutation
In brief
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.
Key facts
- Study ID
- NCT04764474
- Run by
- Hutchmed
- People needed
- 46
- Starts
- 2021-04-12
- Expected to finish
- 2025-01-15
- Last updated by the study team
- 2026-01-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center — Orange, California, United States
- Winship Cancer Institute - Emory University — Atlanta, Georgia, United States
- University of Massachusetts Medical School — Worcester, Massachusetts, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Froedtert-Medical College of WI — Milwaukee, Wisconsin, United States
- Clinica Universidad de Navarra — Pamplona, Navarre, Spain
- Hospital Clinico Universitario de Valencia — Valencia, Valencia, Spain
- Hospital Universitario La Fe — Valencia, Valencia, Spain
- Hospital Universitario Vall d'Hebron — Barcelona, Spain
- Institut Catala d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i Reynals — Barcelona, Spain
- START Madrid - Hospital Universitario Fundacion Jimenez Diaz — Madrid, Spain
- Hospital Universitario 12 de Octubre — Madrid, Spain
- Hospital Universitario de Salamanca — Salamanca, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.